Skip to main content
. 2017 Aug 22;7(14):3585–3594. doi: 10.7150/thno.21471

Figure 4.

Figure 4

Distribution of TMITs, as well as mutation burden and neoantigen number according to TMIT, across certain cancer types. Proportion of TMITs as defined by PD-L1 and CD8A expression in CESC, COAD, KIRC, LIHC, LUAD (A), and by PD-L1 and CYT expression in BLCA, BRCA, CESC, COAD, LUAD, SKCM, STAD, and THCA (B). Boxplot distributions of log 2-transformed values of the number of mutations/neoantigens according to TMIT, and histogram distributions of TMITs according to mutation/neoantigen status of these cancer types (C-N). P values are calculated by Wilcoxon rank-sum test as compared to TMIT I (*P < 0.05, **P < 0.001). RPART, Recursive Partitioning and Regression Trees; TMIT, tumor microenvironment immune type.